1. null
    Doina Ivan et al, 2016 CrossRef
  2. Prognostic values of DNA mismatch repair genes in ovarian cancer patients treated with platinum-based chemotherapy
    Chuchu Zhao et al, 2018, Arch Gynecol Obstet CrossRef
  3. When biomarkers define a drug indication
    Jan Trøst Jørgensen, 2018, Expert Review of Molecular Diagnostics CrossRef
  4. The clinicopathological features and prognosis of tumor MSI in East Asian colorectal cancer patients using NCI panel
    Jianmin Zheng et al, 2018, Future Oncology CrossRef
  5. Deficient mismatch repair and RAS mutation in colorectal carcinoma patients: a retrospective study in Eastern China
    Xiangyan Zhang et al, 2018 CrossRef
  6. Molecular classification and precision therapy of cancer: immune checkpoint inhibitors
    Yingyan Yu, 2018, Front. Med. CrossRef
  7. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
    Michael M. Boyiadzis et al, 2018, j. immunotherapy cancer CrossRef
  8. Use of immunohistochemical versus microsatellite analyses as markers for colorectal cancer
    Utku Tantoğlu et al, 2018 CrossRef
  9. Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions
    Luis V. Syro et al, 2018, Front. Endocrinol. CrossRef
  10. MicroRNAs in the etiology of colorectal cancer: pathways and clinical implications
    Ashlee M. Strubberg et al, 2017, Dis. Model. Mech. CrossRef
  11. Anomalies de la réparation de l’ADN et cancers gynécologiques
    Aurélie Auguste et al, 2017, Bulletin du Cancer CrossRef
  12. Mismatch repair deficiency assessment by immunohistochemistry: for Lynch syndrome screening and beyond
    Hui-li Wong et al, 2018, Future Oncology CrossRef
  13. Molecular and Immunohistochemical Markers with Prognostic and Predictive Significance in Liver Metastases from Colorectal Carcinoma
    Gianluca Lopez et al, 2018, IJMS CrossRef
  14. Identification of Lynch syndrome risk variants in the Romanian population
    Paul D. Iordache et al, 2018, J Cell Mol Med CrossRef
  15. Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers
    Vanessa L. Hale et al, 2018, Genome Med CrossRef
  16. Architects meets Repairers: The interplay between homeobox genes and DNA repair
    Bruno César Feltes, 2018, DNA Repair CrossRef
  17. Épidémiologie des tumeurs MSI : fréquence des tumeurs MSI en fonction de la localisation du cancer et de son stade
    Raphaël Colle et al, 2018, Bulletin du Cancer CrossRef
  18. Microsatellite instability test using peptide nucleic acid probe-mediated melting point analysis: a comparison study
    Mi Jang et al, 2018, BMC Cancer CrossRef
  19. Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability
    Nicola Fusco et al, 2018 CrossRef
  20. Advances in the Study of Microsatellite Instability and Clinical and Prognosis of Gastric Cancer
    颖晨 史, 2019, ACRPO CrossRef
  21. Clinical implications of the genetics of sporadic colorectal cancer
    Jesse Fischer et al, 2019, ANZ Journal of Surgery CrossRef
  22. Corticotroph Pituitary Carcinoma in a Patient With Lynch Syndrome (LS) and Pituitary Tumors in a Nationwide LS Cohort
    Daniel Bengtsson et al, 2017 CrossRef
  23. Identification of recurrent mutational events in anorectal melanoma
    Hui Min Yang et al, 2017, Mod Pathol CrossRef
  24. Immune check-point in endometrial cancer
    Francesca De Felice et al, 2019, Int J Clin Oncol CrossRef
  25. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
    C Luchini et al, 2019 CrossRef
  26. Pembrolizumab in advanced gastrointestinal malignancies with defective dna mismatch repair: A case series
    DavidD Stenehjem et al, 2018, J Immunother Precis Oncol CrossRef
  27. Mismatch Repair/Microsatellite Instability Testing Practices among US Physicians Treating Patients with Advanced/Metastatic Colorectal Cancer
    null Eriksson et al, 2019, JCM CrossRef
  28. Mikrosatelliteninstabilität
    W. Dietmaier et al, 2019, Pathologe CrossRef
  29. An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome
    Manon Suerink et al, 2019, Genet Med CrossRef
  30. null
    Bhumika Patel, 2019 CrossRef
  31. Number of Intratumoral T Lymphocytes Is Associated With Lymph Node Size, Lymph Node Harvest, and Outcome in Node-Negative Colon Cancer
    Bruno Märkl et al, 2016, Am J Clin Pathol CrossRef
  32. null
    Giuseppe Palmieri et al, 2020 CrossRef
  33. DNA damage response as a therapeutic target in gynecological cancers
    Alexandra Leary et al, 2016, Current Opinion in Oncology CrossRef
  34. Microsatellite instability in melanoma
    Ondřej Kubeček et al, 2016, Melanoma Research CrossRef
  35. Ovarian metastasis from uveal melanoma with MLH1/PMS2 protein loss in a patient with germline MLH1 mutated Lynch syndrome: consequence or coincidence?
    João Lobo et al, 2017, Virchows Arch CrossRef
  36. Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?
    Giuseppe Palmieri et al, 2017, J Transl Med CrossRef
  37. Molecular Profiling in Colon Cancer: Where Are We Now?
    Roberto S. Fratamico et al, 2017, Curr Colorectal Cancer Rep CrossRef
  38. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine
    Laetitia Nebot-Bral et al, 2017, European Journal of Cancer CrossRef
  39. Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma
    R. J. Head et al, 2017, Cancer Biology & Therapy CrossRef
  40. Classification of Endometrial Carcinoma
    Mohammed Akhtar et al, 2019, Advances In Anatomic Pathology CrossRef
  41. A Pediatric Case of Glioblastoma Multiforme Associated With a Novel Germline p.His112CysfsTer9 Mutation in the MLH1 Gene Accompanied by a p.Arg283Cys Mutation in the TP53 Gene: A Case Report
    Aleksandra Stajkovska et al, 2019, Front. Genet. CrossRef
  42. Microsatellite instability screening in colorectal adenomas to detect Lynch syndrome patients? A systematic review and meta-analysis
    Parag D. Dabir et al, 2019, Eur J Hum Genet CrossRef
  43. Melanoma and Vitiligo: In Good Company
    Cristina Maria Failla et al, 2019, IJMS CrossRef
  44. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future.
    Sona Vodenkova et al, 2020, Pharmacol Ther CrossRef
  45. Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes
    Jaclyn F. Hechtman et al, 2019, Mod Pathol CrossRef
  46. Reliable Clinical MLH1 Promoter Hypermethylation Assessment using a High-Throughput Genome-Wide Methylation Array Platform
    Jamal K. Benhamida et al, 2019, The Journal of Molecular Diagnostics CrossRef
  47. The somatic mutation landscape of the human body
    Pablo E. García-Nieto et al, 2019, Genome Biol CrossRef
  48. Cell-Selective Cytotoxicity of a Fluorescent Rhodium Metalloinsertor Conjugate Results from Irreversible DNA Damage at Base Pair Mismatches
    Adela Nano et al, 2020, Biochemistry CrossRef
  49. null
    Moyra Smith, 2020 CrossRef
  50. Tumour characteristics provide evidence for germline mismatch repair missense variant pathogenicity
    Shuwei Li et al, 2020, J Med Genet CrossRef
  51. Temozolomide therapy for aggressive pituitary tumours – current understanding and future perspectives
    Pia Burman et al, 2020, Rev Endocr Metab Disord CrossRef
  52. Decoding the Genomic Report for Radiologists
    Daniel A. Smith et al, 2020, American Journal of Roentgenology CrossRef
  53. A Novel Germline MLH1 In-Frame Deletion in a Slovenian Lynch Syndrome Family Associated with Uncommon Isolated PMS2 Loss in Tumor Tissue.
    Gašper Klančar et al, 2020, Genes (Basel) CrossRef
  54. null
    Mingxuan Xu et al, 2020 CrossRef
  55. Downregulation of GLYR1 contributes to microsatellite instability colorectal cancer by targeting p21 via the p38MAPK and PI3K/AKT pathways
    Zhiyan Hu et al, 2020, J Exp Clin Cancer Res CrossRef
  56. Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents.
    Trinayan Kashyap et al, 0 CrossRef
  57. Hypermutation and microsatellite instability in gastrointestinal cancers
    Kizuki Yuza et al, 2017, Oncotarget CrossRef
  58. Less correlation between mismatch repair proteins deficiency and decreased expression of HLA class I molecules in endometrial carcinoma: a different propensity from colorectal cancer
    Tasuku Mariya et al, 2020, Med Mol Morphol CrossRef
  59. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
    Monica Marabelli et al, 2020, Digestive and Liver Disease CrossRef
  60. MLH1 and MSH2 mismatch repair protein profile using immunohistochemistry in Nepalese colorectal cancer patients
    Matrika Bhattarai et al, 2020, Med J Indones CrossRef
  61. Molecular Mechanisms Contributing Bacterial Infections to the Incidence of Various Types of Cancer
    Salah A. Sheweita et al, 2020, Mediators of Inflammation CrossRef
  62. Immunohistochemical mismatch repair proteins expression as a tool to predict the melanoma immunotherapy response
    Giovanni Ponti et al, 2019, mol clin onc CrossRef
  63. null
    Konstantin Holzapfel et al, 2020 CrossRef
  64. Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer
    Byung Woog Kang et al, 2020, ESMO Open CrossRef
  65. Clinical implications of mismatch repair deficiency screening in patients with mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN)
    Lei Lou et al, 2020, European Journal of Surgical Oncology CrossRef
  66. The DNA Glycosylase NEIL2 Suppresses Fusobacterium-Infection-Induced Inflammation and DNA Damage in Colonic Epithelial Cells
    Ibrahim M. Sayed et al, 2020, Cells CrossRef
  67. Colorectal Cancer and Probiotics: Are Bugs Really Drugs?
    Purushottam Lamichhane et al, 2020, Cancers CrossRef
  68. Cáncer de endometrio en el síndrome de Lynch
    H. Khider et al, 2020, EMC - Ginecología-Obstetricia CrossRef
  69. Interface of DNA Repair and Metabolism
    Daniel Marconi et al, 2020, Curr. Tissue Microenviron. Rep. CrossRef
  70. null
    Bhumika Patel, 2020 CrossRef
  71. Emerging Role of Immunotherapy for Colorectal Cancer with Liver Metastasis

    Xianzhe Yu et al, 2020, OTT CrossRef
  72. Clinicopathological and Molecular Profiles of Sporadic Microsatellite Unstable Colorectal Cancer with or without the CpG Island Methylator Phenotype (CIMP)
    Shih-Ching Chang et al, 2020, Cancers CrossRef
  73. Evaluating Mismatch Repair/Microsatellite Instability Status Using Cytology Effusion Specimens to Determine Eligibility for Immunotherapy
    Elizabeth M. Jacobi et al, 2021 CrossRef
  74. DNA-protein biomarkers for immunotherapy in the era of precision oncology
    Binnari Kim et al, 2021, J Pathol Transl Med CrossRef
  75. null
    Hideki Yamamoto et al, 2021 CrossRef
  76. null
    Bryony A. Thompson et al, 2021 CrossRef
  77. Mismatch Repair Status Characterization in Oncologic Pathology: Taking Stock of the Real-World Possibilities
    Roberto Piciotti et al, 2021, JMP CrossRef
  78. Industrializing engineered autologous T cells as medicines for solid tumours
    Cedrik M. Britten et al, 2021, Nat Rev Drug Discov CrossRef
  79. Are Molecular Alterations Linked to Genetic Instability Worth to Be Included as Biomarkers for Directing or Excluding Melanoma Patients to Immunotherapy?
    Giuseppe Palmieri et al, 2021, Front. Oncol. CrossRef
  80. Expression of Mismatch Repair Proteins in Merkel Cell Carcinoma
    Thilo Gambichler et al, 2021, Cancers CrossRef
  81. Rhodium Complexes Targeting DNA Mismatches as a Basis for New Therapeutics in Cancers Deficient in Mismatch Repair
    Adela Nano et al, 2021, Biochemistry CrossRef
  82. Immunotherapy in endometrial cancer: rationale, practice and perspectives
    Wenyu Cao et al, 2021, Biomark Res CrossRef
  83. Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy
    M. Repetto et al, 2021, European Journal of Cancer CrossRef
  84. Progress and challenges of immunotherapy in triple-negative breast cancer
    Yinxing Zhu et al, 2021, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
  85. Upregulated NLGN1 predicts poor survival in colorectal cancer
    Qian Yu et al, 2021, BMC Cancer CrossRef
  86. Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment
    Yunfeng Song et al, 2021, OTT CrossRef
  87. The prognostic and clinicopathological roles of microsatellite instability, PD-L1 expression and tumor-infiltrating leukocytes in familial adenomatous polyposis
    Min Shu Ma et al, 2021, European Journal of Surgical Oncology CrossRef
  88. The potentiality of immunotherapy for sarcomas: a summary of potential predictive biomarkers
    Jin Liang et al, 2020, Future Oncology CrossRef
  89. Mismatch repair deficiency in canine neoplasms
    Sakuya Inanaga et al, 2021, Vet Pathol CrossRef
  90. YB-1 Oncoprotein Controls PI3K/Akt Pathway by Reducing Pten Protein Level
    Antonella Delicato et al, 2021, Genes CrossRef
  91. null
    Fiorella Guadagni et al, 2021 CrossRef
  92. Deciphering the Genomic Landscape and Pharmacological Profile of Uncommon Entities of Adult Rhabdomyosarcomas
    Alessandro De Vita et al, 2021, IJMS CrossRef
  93. Genomic instability, inflammatory signaling and response to cancer immunotherapy
    Mengting Chen et al, 2021, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
  94. Examination of Gene Loss in the DNA Mismatch Repair Pathway and Its Mutational Consequences in a Fungal Phylum
    Megan A Phillips et al, 2021 CrossRef
  95. Mutation rate and spectrum in obligately outcrossing Caenorhabditis elegans mutation accumulation lines subjected to RNAi-induced knockdown of the mismatch repair gene msh-2
    Vaishali Katju et al, 2021 CrossRef
  96. Using amide proton transfer-weighted MRI to non-invasively differentiate mismatch repair deficient and proficient tumors in endometrioid endometrial adenocarcinoma
    Yuan Li et al, 2021, Insights Imaging CrossRef
  97. Microsatellite Instability Assessment by Immunohistochemistry in Acute Myeloid Leukemia: A Reappraisal and Review of the Literature
    Siba El Hussein et al, 2021, Clinical Lymphoma Myeloma and Leukemia CrossRef
  98. Recent insights into the use of immune checkpoint inhibitors in gastric cancer
    Soraia Rodrigues et al, 2022 CrossRef
  99. Multi-Omics Prognostic Signatures Based on Lipid Metabolism for Colorectal Cancer
    YuanLin Sun et al, 2022, Front. Cell Dev. Biol. CrossRef
  100. Proficiency Testing to Improve Interobserver Agreement for Mismatch Repair Deficiency Immunohistochemistry: An Invitation to Join CBQA Readout
    Raul S. Gonzalez et al, 2022 CrossRef
  101. Recent Advances in Therapeutic Application of DNA Damage Response Inhibitors against Cancer
    Stina George Fernandes et al, 2022, ACAMC CrossRef
  102. The CtIP-CtBP1/2-HDAC1-AP1 transcriptional complex is required for the transrepression of DNA damage modulators in the pathogenesis of osteosarcoma
    Xun Chen et al, 2022, Translational Oncology CrossRef
  103. Current Role of Immunotherapy in Gastric, Esophageal and Gastro-Esophageal Junction Cancers—A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference
    Karen Mulder et al, 2022, Current Oncology CrossRef
  104. Colorectal cancer immunotherapy-Recent progress and future directions
    Wen Zhao et al, 2022, Cancer Letters CrossRef
  105. Relationship of microsatellite instability to mismatch repair deficiency in malignant tumors of dogs
    Sakuya Inanaga et al, 2022, Veterinary Internal Medicne CrossRef
  106. Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors
    Csongor György Lengyel, 2021, CDT CrossRef
  107. Marker assessments in ER‐ positive breast cancers: old markers, new applications?
    Joshua J X Li et al, 2022, Histopathology CrossRef
  108. Gut microbiota distinct between colorectal cancers with deficient and proficient mismatch repair: A study of 230 CRC patients
    Min Jin et al, 2022, Front. Microbiol. CrossRef
  109. Molecular Pathology of Gastric Cancer
    Moonsik Kim et al, 2022, J Gastric Cancer CrossRef
  110. Unique genomic and neoepitope landscapes across tumors: a study across time, tissues, and space within a single lynch syndrome patient
    Tanya N. Phung et al, 2020, Sci Rep CrossRef
  111. Tissue microarrey: a potential cost-effective approach for mismatch repair testing in colorectal cancer
    Shai Farkash et al, 2022, BMC Gastroenterol CrossRef
  112. An assessment of mismatch repair deficiency in ovarian tumours at a public hospital in Johannesburg, South Africa
    S R De Klerk et al, 2022, S Afr J Obstet Gynae CrossRef
  113. Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control
    Kyle Concannon et al, 2023, Molecular Cell CrossRef